logo

For the Inventor, By the Inventor

Milan, Italy

Italfarmaco Spa


USPTO Granted Patents = 48



Trademarks = 7

Forward Citations = 245

Loading Chart...
Loading Chart...

88 inventors (with patents filed for the assignee):

goldMedal Paolo Mascagni (21 out of 21 patents)

silverMedal Flavio Leoni (10 out of 10 patents)

bronzeMedal Giancarlo Sportoletti (10 out of 12 patents)

4.  Massimo Pinori (8 out of 13 patents)

5.  Gianni Gromo (7 out of 7 patents)

6.  Pietro Cremonesi (7 out of 7 patents)

7.  Francesca Benedini (5 out of 34 patents)

8.  Alberto Sala (5 out of 10 patents)

9.  Gianluca Fossati (4 out of 4 patents)

10.  Giorgio Bertolini (4 out of 19 patents)

11.  Roberta Cereda (4 out of 4 patents)

12.  Barbara Vergani (3 out of 3 patents)

13.  Maria Lattanzio (3 out of 3 patents)

14.  Gianfranco Pavich (3 out of 3 patents)

15.  Daniela Modena (3 out of 3 patents)


Core Competencies:
Selective HDAC6 Inhibitors
Antitumor Activity
Histone Deacetylase Inhibitors
Hydroxamic Acid Derivatives
Anti-inflammatory Activity
Heparin Derivatives
Cytoprotective Guanidine Derivatives
Glycosaminoglycan Salts
Oral Suspensions
Peptides
Enzymatic Reactions
Pharmaceutical Compositions

48 patents:

1. 12129224 - Process for preparing {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate having high purity (2024-10-29),
2. 11351178 - Selective HDAC6 inhibitors (2022-06-07),
3. 10745696 - HC-CDR3-only libraries with reduced combinatorial redundancy and optimized loop length distribution (2020-08-18),
4. 10688047 - Physically and chemically stable oral suspensions of givinostat (2020-06-23),
5. 10590101 - Benzo-N-hydroxy amide compounds having antitumor activity (2020-03-17),
6. 9867799 - Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy (2018-01-16),
7. 9522127 - Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes (2016-12-20),
8. 9421184 - Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy (2016-08-23),
9. 8937152 - Non-selective somatostatin analogues (2015-01-20),
10. 8765150 - Riluzole aqueous suspensions (2014-07-01),
11. 8637702 - Derivatives of N-hydroxybenzamide for treating HIV infections (2014-01-28),
12. 8227515 - Use of hydroxamic acid derivatives for the preparation of anti-tumour medicaments (2012-07-24),
13. 8217079 - Method for treating Philadelphia-negative myeloproliferative syndromes (2012-07-10),
14. 7635788 - Alpha-amino acid derivatives with antiinflammatory activity (2009-12-22),
15. 7427620 - Azole derivative useful as antifungal agents with reduced interaction with metabolic cytochromes (2008-09-23),
Italfarmaco S.p.A. is a multinational pharmaceutical company headquartered in Milan, Italy. Founded in 1938, the company focuses on research, development, and commercialization of innovative pharmaceutical products. It offers a wide range of therapeutic solutions in various therapeutic areas including neuroscience, oncology, respiratory, and rare diseases. Italfarmaco is committed to improving patient health and well-being through continuous innovation and scientific excellence.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

48 Patents

#36 in Milan

#168 in Italy

#14,124 in the World

...
Milan, Italy

Italfarmaco Spa

Forward Citations = 245

88 inventors:

goldMedal Paolo Mascagni (21 out of 21 patents)

silverMedal Flavio Leoni (10 out of 10 patents)

bronzeMedal Giancarlo Sportoletti (10 out of 12 patents)

4.  Massimo Pinori (8 out of 13 patents)

5.  Gianni Gromo (7 out of 7 patents)

Please report any incorrect information to support@idiyas.com
Loading…